94 results on '"Niu, Dau-Ming"'
Search Results
2. Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.
- Author
-
Chang, Wen-Hsin, Niu, Dau-Ming, Lu, Chi-Yu, Lin, Shyr-Yi, Liu, Ta-Chih, and Chang, Jan-Gowth
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *RNA splicing , *AMILORIDE , *CANCER cells , *HISTONES - Abstract
While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Development of a gene therapy for cardiac type Fabry disease: A gene editing strategy.
- Author
-
Chen, Yun-Ru, Niu, Dau-Ming, Lu, Yu-Ying, Huang, Chun-Ying, Cheng, Yen-Fu, Chiang, Yu-Ting, and Yen, Ching-Tzu
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *GENOME editing , *GENE therapy - Published
- 2023
- Full Text
- View/download PDF
4. Living donor liver transplantation using a graft from a donor with Dubin-Johnson syndrome.
- Author
-
Liu, Chinsu, Niu, Dau-Ming, Hsia, Cheng-Yuan, Loong, Che-Chuan, Lin, Niang-Cheng, Tsai, Hsin-Lin, Tsou, Mei-Yung, and Chin, Taiwai
- Subjects
- *
LIVER transplantation , *ORGAN donors , *IMMUNOSUPPRESSION , *AMINO acids , *AMINO compounds - Abstract
Liu C, Niu D-M, Hsia C-Y, Loong C-C, Lin N-C, Tsai H-L, Tsou M-Y, Chin T. Living donor liver transplantation using a graft from a donor with Dubin-Johnson syndrome. Pediatr Transplantation 2012: 16: E25-E29. © 2010 John Wiley & Sons A/S. Abstract: DJS is an autosomal recessive disorder that causes an increase in conjugated bilirubin without elevation of liver enzymes. Most patients are asymptomatic and have normal life spans, but to the best of our knowledge, their livers have never been reported to be grafts in liver transplantation. Herein, we report an infant patient with MMA that received a partial liver graft from his mother, who had DJS. A biliary anastomosis stricture was noted five months after transplantation and was successfully treated with radiological interventions. Otherwise, the patient's liver functions were normal, and a liver biopsy showed a pathognomonic picture of DJS nine months after the transplantation. The patient was followed for one yr, and the results were satisfactory for an increase in oral intake and protein uptake, no recurrence of metabolic stroke and there was a gradual catch-up with regard to physical development despite having a persistently abnormal profile of amino acid analysis. From the experience of our case, we suggest that a liver from a donor with DJS can be used as a graft for liver transplantation, although long-term follow-up is mandatory to examine the grafted liver under the use of immunosuppressive medications. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Family caregiver distress with children having rare genetic disorders: a qualitative study involving Russell-Silver Syndrome in Taiwan.
- Author
-
Weng, Hsin-Ju, Niu, Dau-Ming, Turale, Sue, Tsao, Lee-Ing, Shih, Fu-Jong, Yamamoto-Mitani, Noriko, Chang, Chun-Chi, and Shih, Fu-Jin
- Subjects
- *
PSYCHOLOGY of caregivers , *CONTENT analysis , *DECISION making , *INTERVIEWING , *PATIENT-family relations , *RESEARCH , *STATISTICAL sampling , *SOUND recordings , *SYNDROMES , *TRANSLATIONS , *QUALITATIVE research , *SOCIAL support , *THEMATIC analysis , *BURDEN of care - Abstract
Aim. To extend nursing knowledge of distress experienced by family caregivers of children with rare genetic disorders, by exploring the perspectives of caregivers of children with Russell-Silver Syndrome in Taiwan. Background. Caring for a child with a rare genetic disorder often has profound effects on families, especially when diagnosis and treatment is complex or not yet well developed, such as that in Russell-Silver Syndrome (or Silver-Russell syndrome). This disorder causes dwarfism and developmental difficulties, requiring long-term care planning. Previous research has focused mostly on medical care, but little is known about families' perspectives of caring difficulties, the help they need and nursing care required. Design. An exploratory qualitative approach was used to inform this study. Methods. Family caregivers, whose children were undergoing medical care in a leading Taiwan medical centre, were invited to participate in face-to-face, in-depth interviews. Data were analysed by content analysis. Results. Fifteen caregivers including 11 mothers, two fathers and two grandmothers participated. Five major themes and 13 sub-themes of care-giving distress were identified: endless psychological worries; the lengthy process to confirm a medical diagnosis; adjustment efforts in modifying family roles; dilemmas in deciding between Western or Chinese traditional medicine; and negative responses to society's concerns. Their primary sources of support were spouses, parents and health professionals, accordingly. Conclusion. Complex physio-psycho-social and decision-making distress in caring for children with a rare genetic disorder were systematically revealed from the perspectives of ethnic-Chinese family caregivers. Relevance to clinical practice. Long-term care plans for children with a rare genetic disorder such as Russell-Silver Syndrome need to focus on positive dynamic family interactions, life-stage development and family caregiver support. Research on care-giving in rare genetic disorders is also warranted across cultures and countries to develop a substantial knowledge basis for nursing practice. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan
- Author
-
Niu, Dau-Ming
- Subjects
- *
METABOLIC disorders , *PTERIDINES , *PHENOTYPES , *NEUROTRANSMITTERS , *MEDICAL screening - Abstract
Abstract: 6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency is the most frequent form of tetrahydrobiopterin (BH4) deficiency related to hyperphenylalaninemia (HPA). PTPS deficiency may not only cause a typical phenylketonuric phenotype, but is also accompanied by various neurological signs and symptoms due to impaired synthesis of catecholamines and serotonin. The treatment of PTPS deficiency is aimed at normalizing phenylalanine levels and brain neurotransmitters. The BH4 can be administered to normalize phenylalanine (PHE) levels easily, but, owing to severe side effects, the neurotransmitters, l-DOPA and 5-hydroxytryptophan, should be administered for these patients very carefully. However, optimal dosage of the neurotransmitters for PTPS deficiency patients is difficult to be determined. Several reports have described unsatisfied outcomes in a large percentage of patients with PTPS deficiency, despite early detection and treatment. Between 1988 and 2000, 12 newborns with PTPS deficiency identified by newborn screening were referred and received early treatment at our hospital. The mean IQ score of these 12 patients was 96.7 (±9.7; range: 86–119), which is considerably higher than previous reports of other populations of PTPS-deficient patients. In this report, we reviewed the disorders of BH4 briefly and then described treatments of our PTPS-deficient patients. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Identification of a microdeletion at Xp22.13 in a Taiwanese family presenting with Nance-Horan syndrome.
- Author
-
Liao, Hsiao-Mei, Niu, Dau-Ming, Chen, Yan-Jang, Fang, Jye-Siung, Chen, Shih-Jen, and Chen, Chia-Hsiang
- Subjects
- *
X chromosome abnormalities , *CATARACT , *TEETH abnormalities , *COMPARATIVE genomic hybridization , *FACIAL abnormalities , *GENETIC disorders , *TAIWANESE people - Abstract
Nance-Horan syndrome (NHS) is a rare X-linked disorder characterized by congenital cataracts, dental anomalies and mental retardation. The disease has been linked to a novel gene termed NHS located at Xp22.13. The majority of pathogenic mutations of the disease include nonsense mutations and small deletions and insertions that lead to truncation of the NHS protein. In this study, we identified a microdeletion of ∼0.92 Mb at Xp22.13 detected by array-based comparative genomic hybridization in two brothers presenting congenital cataract, dental anomalies, facial dysmorphisms and mental retardation. The deleted region encompasses the REPS2, NHS, SCML1 and RAI2 genes, and was transmitted from their carrier mother who presented only mild cataract. Our findings are in line with several recent case reports to indicate that genomic rearrangement involving the NHS gene is an important genetic etiology underlying NHS. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Development of a gene therapy for Fabry disease using adeno-associated viral vector mediated gene transfer.
- Author
-
Niu, Dau-Ming, Chang, Sheng-Kai, Lee, Ya-Ting, Chen, Yun-Ru, Lu, Yung-Hsiu, Hsu, Ting-Rong, Cheng, Chih-ya, Yang, Chia-Feng, and Chu, Tzu-Hung
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *GENE therapy , *GENETIC transformation , *TRANSGENE expression , *TREATMENT effectiveness , *ADENO-associated virus - Published
- 2020
- Full Text
- View/download PDF
9. Subtle brain dysfunction in treated 6-pyruvoyl-tetrahydropterin synthase deficiency: relationship to motor tasks and neurophysiological tests
- Author
-
Kao, Chuen-Der, Niu, Dau-Ming, Chen, Jen-Tse, Shan, Din-E., Lin, Yung-Yang, Wu, Zin-An, and Liao, Kwong-Kum
- Subjects
- *
ACETOLACTATE synthase , *NEUROTRANSMITTERS , *DOPAMINE , *BRAIN - Abstract
6-Pyruvoyl-tetrahydropterin synthase (6PTPS) deficiency is a major cause of biopterin deficiency. 6PTPS patients usually have an elevated serum phenylalanine level, a deficiency of neurotransmitters (serotonin and dopamine), and neurological symptoms, if without treatment. We herein investigated the possibility of neurological dysfunction in early-treated patients. In the study, 12 early-treated 6PTPS patients were studied. Their auditory simple reaction time, movement rhythm variation (MRV), somatosensory evoked potentials to median nerve stimulation, and hand muscle responses to transcranial magnetic stimulation, were measured. MRV is a test of repetitive voluntary movements, and was used with and without auditory cues at 0.3 Hz. The 6PTPS patients had an increased motor threshold but normal motor and sensory central conduction times. They performed very well in simple reactions (6PTPS 208.4±16.7 ms, control 200.3±11.7 ms, p=0.18), but not in continuous tasks. The continuous performance tests showed that MRV had increased in the 6PTPS patients (with cues: 6PTPS 7.35±0.94, control 5.47±0.80, p<0.0001; without cues: 6PTPS 9.87±1.44, control 6.59±0.68, p<0.0001). Without cues, MRV had increased in both the 6PTPS and control groups, but more significantly in the 6PTPS patients (6PTPS 2.51±0.97, control 1.25±0.42; p=0.0001). Our findings indicate that early-treated 6PTPS patients have subtle neurological dysfunctions. They may not maintain movement rhythm as well as normal subjects, even with external cues. Hence, MRV is a good method to assess motor control. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
10. Diagnosis of Congenital Hypothyroidism from Human Anagen Scalp Hair by Infrared Microspectroscopy.
- Author
-
Lin, Shan-Yang, Niu, Dau-Ming, Tu, Chun-Pin, Lin, Hsiu-Lin, Li, Mei-Jane, and Cheng, Yih-Dih
- Subjects
- *
HYPOTHYROIDISM , *FOURIER transform infrared spectroscopy - Abstract
A highly efficient Fourier transform infrared (FT-IR) microscopy was used to determine the biophysical structure of anagen scalp hair roots of neonates suffering from congenital hypothyroidism (CH) due to ectopic thyroid. The present results indicate that the lower composition near 1,053 cm-[sup 1] (also assigned to the aromatic iodide stretching band) in the infrared (IR) spectra of the hair roots for CH patients was directly associated with the lower serum level of T[sub 4] and fT[sub 4], and the elevated TSH levels determined by RIA method. This strongly implies the lower evidence of the aromatic iodide stretching band in the IR spectra of hair roots. These findings suggest that FT-IR microscopy has the potential to become a good diagnostic tool and that hair can be useful as a genetic marker. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
11. Development of a gene therapy for Fabry disease using adeno-associated viral vector mediated gene editing.
- Author
-
Niu, Dau-Ming, Chen, Yun-Ru, and Lu, Yu-Ying
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *GENOME editing , *GENE therapy , *GENETIC vectors , *RNA splicing - Published
- 2021
- Full Text
- View/download PDF
12. Early detection of the irreversible cardiac damages in the adults with late onset Fabry disease in a large cohort study via newborn screening.
- Author
-
Niu, Dau-Ming, Chang, Sheng-Kai, Hsu, Ting-Rong, Cheng, Chihya, Yang, Chia-Feng, Chen, Yun-Ru, Lu, Yung-Hsiu, Hsieh, Yu-Ping, and Chen, Jing-Er
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *NEWBORN screening , *ADULTS , *COHORT analysis , *CARDIAC magnetic resonance imaging - Published
- 2020
- Full Text
- View/download PDF
13. Methylmalonic acidemia/propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups.
- Author
-
Yang, Chia-Feng, Niu, Dau-Ming, Chu, Tzu-Hung, Hu, Rey-Heng, Ho, Ming-Chih, Chien, Yin-Hsiu, Hwu, Wuh-Liang, Lee, Ni-Chung, Lin, Shuan-Pei, Lin, Hsiang-Yu, Liao, Hsuan-Chieh, Chiang, Chuan-Chi, Ho, Huey-Jane, Lai, Chih-Jou, Lin, Niang-Cheng, and Liu, Chin-Su
- Subjects
- *
METHYLMALONIC acid , *LIVER transplantation , *PROPIONYL-CoA carboxylase , *HOMOCYSTINURIA , *PROPIONATES , *ACIDOSIS , *PROPIONYLCARNITINE - Abstract
Background: Most patients with isolated methylmalonic acidemia (MMA) /propionic acidemia (PA) presenting during the neonatal period with acute metabolic distress are at risk for death and significant neurodevelopmental disability. The nationwide newborn screening for MMA/PA has been in place in Taiwan from January, 2000 and data was collected until December, 2016.Results: During the study period, 3,155,263 newborns were screened. The overall incidence of MMA mutase type cases was 1/121,356 (n = 26), 1 cobalamin B was detected and that for PA cases (n = 4) was 1/788,816. The time of referral is 8.8 days for MMA patients, and 7.5 days for PA patients. The MMA mutase type patients have higher AST, ALT, and NH3 values as well as a lower pH value (p < 0.05). The mean age for liver transplantation (LT) is 402 days (range from 0.6-6.7 yr) with 16 out of 20 cases (80.0%) using living donors. The mean admission length shortened from 90.6 days/year (pre-LT) to 5.3 days/year (at 3rd year post-LT) (p < 0.0005). Similarly, the tube feeding ratio decreased from 67.8 to 0.50% (p < 0.00005). The anxiety level of the caregiver was reduced from 33.4 to 27.2 after LT (p = 0.001) and the DQ/IQ performance of the patients was improved after LT from 50 to 60.1 (p = 0.07).Conclusion: MMA/PA patients with LT do survive and have reduced admission time, reduced tube feeding and the caregiver is less anxious. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. Reevaluate current routine histopathologic examinations for Fabry disease- not sensitive enough to identify early globotriaosylceramide accumulation in cardiomyocytes.
- Author
-
Niu, Dau-Ming, Chang, Fu-Pang, Hsu, Ming-Jia, Hsu, Chia-Lin, Hsu, Ting-Rong, Chang, Sheng-kai, and Lu, Yung-Hsiu
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *HISTOPATHOLOGY , *HEART cells , *BIOACCUMULATION , *MEDICAL research - Published
- 2017
- Full Text
- View/download PDF
15. Detection of the first manifestation of the very young children with classical Fabry disease: A study based on newborn screening.
- Author
-
Hsu, TingRong, Niu, Dau-Ming, and Tsai, Yun-An
- Subjects
- *
CHILDREN'S health , *ANGIOKERATOMA corporis diffusum , *MEDICAL screening , *PATIENTS , *DIAGNOSIS ,NEWBORN infant health - Published
- 2016
- Full Text
- View/download PDF
16. Revisited later-onset cardiac type Fabry disease: Cardiac damage progresses in silence (experiences from an extremely high prevalent area, Taiwan).
- Author
-
Niu, Dau-Ming
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *TAIWANESE people , *HEART diseases , *GENE silencing , *MEDICAL research , *DISEASES - Published
- 2016
- Full Text
- View/download PDF
17. When is the best time to start enzyme replacement therapy in patients with cardiac-type Fabry disease? Experience from Taiwan, an area highly prevalent in this cardiac phenotype.
- Author
-
Niu, Dau-Ming, Yu, Wen-Chung, Hsu, Ting-Rong, Chang, Fu-Pang, Sung, Shih-Hsien, and Chu, Tzu-Hung
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *THERAPEUTIC use of enzymes , *PHENOTYPES , *DISEASE prevalence - Published
- 2015
- Full Text
- View/download PDF
18. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS).
- Author
-
Niu, Dau-Ming, Larroque, Sylvain, Liu, Hao-Chuan, Hsu, Ting-Rong, Yang, Chia-Feng, Lin, Hsiang-Yu, Chen, Huei-Fang, Su, Wei-Ting, and Wang, Ya-Hui
- Published
- 2014
- Full Text
- View/download PDF
19. Evaluation of plasma globotriaosylsphingosine (LysoGb3) in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4+919G A)
- Author
-
Niu, Dau-Ming, Liao, Hsuan-Chieh, Huang, Yu-Hsiu, Kao, Shu-Min, Li, Shao-Tzu, Huang, Chun-Kai, Hsieh, Kai-Sheng, Chiu, Pao-Chin, Fu, Yun-Ching, Lin, Ching-Yuang, Tsai, Fuu-Jen, and Chiang, Chuan-Chi
- Published
- 2013
- Full Text
- View/download PDF
20. Evaluate the efficacy of small molecule compounds derived from drug repurposing using cardiac type Fabry disease cell model.
- Author
-
Cheng, Chihya, Lu, Yung-Hsiu, Niu, Dau-Ming, Chen, Yun-Ru, Huang, Chi-Ying, and Chiang, Yu-Ting
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *DRUG repositioning , *SMALL molecules , *DRUG utilization - Published
- 2023
- Full Text
- View/download PDF
21. Association of Fabry Disease with Hearing Loss, Tinnitus, and Sudden Hearing Loss: A Nationwide Population-Based Study.
- Author
-
Cheng, Yen-Fu, Xirasagar, Sudha, Chen, Chin-Shyan, Niu, Dau-Ming, and Lin, Herng-Ching
- Subjects
- *
SENSORINEURAL hearing loss , *ANGIOKERATOMA corporis diffusum , *HEARING disorders , *TINNITUS , *PROPENSITY score matching , *DISEASE prevalence - Abstract
Hearing loss and the related otologic manifestations are receiving increased scrutiny as significant causes of morbidity in Fabry disease. However, the relative risks of auditory deficits among patients with Fabry disease relative to the general population without a diagnosis of Fabry disease have not been studied. This study aims to explore the associations between Fabry disease and hearing-related manifestations using a nationwide population-based dataset. We identified study patients for this cross-sectional study from the 2015–2017 claims databases of the Taiwan Longitudinal Health Insurance Database 2005. We first identified 2312 patients aged over 20 years with a diagnosis of Fabry disease. We used propensity score matching to select five comparison patients per patient with Fabry disease and 11,560 comparison patients without Fabry disease. We used multivariable logistic regressions to estimate the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for tinnitus, hearing loss, and sudden deafness among Fabry disease patients vs. comparison patients. Chi-square tests showed statistically significant differences between patients with and without Fabry disease in the prevalence rates of tinnitus (16.7% vs. 11.7%, p < 0.001), hearing loss (7.5% vs. 6.2%, p = 0.014) and sudden deafness (1.7% vs. 1.0%, p = 0.005). Multiple logistic regression revealed that patients with Fabry disease were more likely to suffer from tinnitus, hearing loss and sudden deafness, with adjusted odds ratios of 1.513 (95% CI = 1.336–1.713), 1.246 (95% CI = 1.047–1.483), and 1.681 (95% CI = 1.166–2.423), respectively. We found that Fabry disease is significantly associated with certain auditory manifestations, including hearing loss, sudden deafness, and tinnitus. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Fabry in the older patient: Clinical consequences and possibilities for treatment.
- Author
-
Lidove, Olivier, Barbey, Frédéric, Niu, Dau-Ming, Brand, Eva, Nicholls, Kathleen, Bizjajeva, Svetlana, and Hughes, Derralynn A.
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *THERAPEUTICS , *OLDER patients , *MEDICAL decision making , *ALPHA-galactosidase , *HYPERTENSION , *GLOMERULAR filtration rate - Abstract
Baseline demographic and phenotypic characteristics of patients aged ≥ 50 years in the Fabry Outcome Survey (Shire; data extracted June 2014) were compared with younger adults to investigate potential factors influencing treatment decisions in later life. Age groups were defined using age at treatment initiation or at FOS entry for untreated patients: 18–49 ( n = 1344; 49.5% male; 64.6% received agalsidase alfa enzyme replacement therapy [ERT]); 50–64 ( n = 537; 35.4% male; 74.3% treated); 65–74 ( n = 137; 32.1% male; 68.6% treated); and ≥ 75 years ( n = 26; 26.9% male; 50.0% treated). Successive age groups showed higher median age at first symptom and diagnosis. Median alpha-galactosidase A activity, measured as percentage activity of the midpoint of the normal range, was much greater in females than males of all groups except ≥ 75 years (33.4% in females; 27.8% in males). Patients aged ≥ 75 years showed greater values than patients aged 18–49 years for median left ventricular mass indexed to height (62.7 vs 42.4 g/m 2.7 ), mean ventricular wall thickness (15.0 vs 10.0 mm) and prevalence of hypertension (57.7% vs 21.8%), and lower median estimated glomerular filtration rate (Modification of Diet in Renal Disease: 65.6 vs 98.5 mL/min/1.73 m 2 ). Larger proportions in the groups aged ≥ 50 exhibited cardiac and/or cerebrovascular manifestations compared with patients aged 18–49 years. The smaller proportion of patients receiving ERT aged ≥ 75 years compared with the younger groups might reflect relatively milder disease burden or physician/patient reluctance to initiate/continue ERT at this age. Further studies are needed to increase knowledge of Fabry disease and ERT in later life. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan.
- Author
-
Lin, Hsiang-Yu, Chang, Ya-Hui, Lee, Chung-Lin, Tu, Yuan-Rong, Lo, Yun-Ting, Hung, Pei-Wen, Niu, Dau-Ming, Liu, Mei-Ying, Liu, Hsin-Yun, Chen, Hsiao-Jan, Kao, Shu-Min, Wang, Li-Yun, Ho, Huey-Jane, Chuang, Chih-Kuang, and Lin, Shuan-Pei
- Subjects
- *
NEWBORN screening , *LYSOSOMES , *HEMATOPOIETIC stem cell transplantation , *TANDEM mass spectrometry , *MUCOPOLYSACCHARIDOSIS , *ENZYME replacement therapy - Abstract
Background: Mucopolysaccharidosis II (MPS II) is an X-linked disorder resulting from a deficiency in lysosomal enzyme iduronate-2-sulfatase (IDS), which causes the accumulation of glycosaminoglycans (GAGs) in the lysosomes of many tissues and organs, leading to progressive cellular dysfunction. An MPS II newborn screening program has been available in Taiwan since 2015. The aim of the current study was to collect and analyze the long-term follow-up data of the screen-positive subjects in this program. Methods: From August 2015 to April 2022, 548,624 newborns were screened for MPS II by dried blood spots using tandem mass spectrometry, of which 202 suspected infants were referred to our hospital for confirmation. The diagnosis of MPS II was confirmed by IDS enzyme activity assay in leukocytes, quantitative determination of urinary GAGs by mass spectrometry, and identification of the IDS gene variant. Results: Among the 202 referred infants, 10 (5%) with seven IDS gene variants were diagnosed with confirmed MPS II (Group 1), 151 (75%) with nine IDS gene variants were classified as having suspected MPS II or pseudodeficiency (Group 2), and 41 (20%) with five IDS gene variants were classified as not having MPS II (Group 3). Long-term follow-up every 6 months was arranged for the infants in Group 1 and Group 2. Intravenous enzyme replacement therapy (ERT) was started in four patients at 1, 0.5, 0.4, and 0.5 years of age, respectively. Three patients also received hematopoietic stem cell transplantation (HSCT) at 1.5, 0.9, and 0.6 years of age, respectively. After ERT and/or HSCT, IDS enzyme activity and the quantity of urinary GAGs significantly improved in all of these patients compared with the baseline data. Conclusions: Because of the progressive nature of MPS II, early diagnosis via a newborn screening program and timely initiation of ERT and/or HSCT before the occurrence of irreversible organ damage may lead to better clinical outcomes. The findings of the current study could serve as baseline data for the analysis of the long-term effects of ERT and HSCT in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.
- Author
-
Beck, Michael, Ramaswami, Uma, Hernberg-Ståhl, Elizabeth, Hughes, Derralynn A., Kampmann, Christoph, Mehta, Atul B., Nicholls, Kathleen, Niu, Dau-Ming, Pintos-Morell, Guillem, Reisin, Ricardo, West, Michael L., Schenk, Jörn, Anagnostopoulou, Christina, Botha, Jaco, and Giugliani, Roberto
- Subjects
- *
INFORMED consent (Medical law) , *ENZYME replacement therapy , *ANGIOKERATOMA corporis diffusum , *SCIENTIFIC knowledge , *MEDICAL practice , *MEDICAL registries - Abstract
Background: Patient registries provide long-term, real-world evidence that aids the understanding of the natural history and progression of disease, and the effects of treatment on large patient populations with rare diseases. The year 2021 marks the 20th anniversary of the Fabry Outcome Survey (FOS), an international, multicenter, observational registry (NCT03289065). The primary aims of FOS are to broaden the understanding of Fabry disease (FD), an X-linked lysosomal storage disorder, and to improve the clinical management of affected patients. Here, we review the history of FOS and the analyses and publications disseminated from the registry, and we discuss the contributions FOS studies have made in understanding FD.Results: FOS was initiated in April 2001 and, as of January 2021, 4484 patients with a confirmed diagnosis and patient informed consent have been enrolled from 144 centers across 26 countries. Data from FOS have been published in nearly 60 manuscripts on a wide variety of topics relevant to FD. Analyses of FOS data have investigated the long-term effectiveness and safety of enzyme replacement therapy (ERT) with agalsidase alfa and its effects on morbidity and mortality, as well as the benefits of prompt and early treatment with agalsidase alfa on the progression of cardiomyopathy and the decline in renal function associated with FD. Based on analyses of FOS data, ERT with agalsidase alfa has also been shown to improve additional signs and symptoms of FD experienced by patients. FOS data analyses have provided a better understanding of the natural history of FD and the specific populations of women, children, and the elderly, and have provided practical tools for the study of FD. FOS has also provided methodology and criteria for assessing disease severity which contributed to the continuous development of medical practice in FD and has largely improved our understanding of the challenges and needs of long-term data collection in rare diseases, aiding in future rare disease real-world evidence studies.Conclusion: FOS over the last 20 years has substantially increased the scientific knowledge around improved patient management of FD and continues to expand our understanding of this rare disease. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. Safety and long‐term outcomes of early liver transplantation for pediatric methylmalonic acidemia patients.
- Author
-
Lin, Niang‐Cheng, Tsai, Hsin‐Lin, Chen, Cheng‐Yen, Yeh, Yi‐Ting, Lei, Hao‐Jan, Chou, Shu‐Cheng, Chung, Meng‐Hsuan, Yang, Chia‐Feng, Niu, Dau‐Ming, Loong, Che‐Chuan, Hsia, Cheng‐Yuan, and Liu, Chin‐Su
- Subjects
- *
LIVER transplantation , *ACIDOSIS , *KIDNEY physiology , *SURVIVAL rate , *NEWBORN screening - Abstract
Background: LT is a treatment option for MMA patients, but renal function impairment is one of the long‐term concerns. The aim of this study was to evaluate the outcomes of early LT in these patients. Methods: A total of 11 MMA mut‐type patients (including 10 mut0 cases and 1 mut‐case) who received LT in our institute were reviewed. Their metabolic profiles were compared between the pre/post‐transplant periods. Their immunosuppressant and renal function changes after transplantation were assessed. Results: After a mean follow‐up of 97.5 ± 38.4 months, there were two deaths, and the actual survival rate was 81.8%. Their metabolic profiles had improved (mean blood ammonia level 366.8 ± 105.5 vs. 53.1 ± 17.4 μg/dl, p <.001; C3/C2 ratio 2.68 ± 0.87 vs. 0.73 ± 0.22, p =.003; mean urine MMA level 920.5 ± 376.6 vs. 196.2 ± 85.4, p =.067), and hospital stays were decreased (78.8 ± 74.5 vs. 7.4 ± 7.0 days/year, p =.009) after transplantation. The mean age at transplant was 1.81 ± 2.02 years old, and nine of these patients received LT before the age of 1.5 years old (early LT). Under prospective immunosuppressant dose reduction, three of these early LT patients discontinued the drug and were sustained for more than 5 years. Most of the patients had a preserved renal function, and no patient is currently on dialysis. Conclusions: In addition to the improvement in the metabolic parameters, early LT in MMA patients may allow for a dose reduction of the immunosuppressant, and the patient's renal function could be preserved in the long term. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Detecting multiple lysosomal storage diseases by tandem mass spectrometry — A national newborn screening program in Taiwan.
- Author
-
Liao, Hsuan-Chieh, Chiang, Chuan-Chi, Niu, Dau-Ming, Wang, Chung-Hsing, Kao, Shu-Min, Tsai, Fuu-Jen, Huang, Yu-Hsiu, Liu, Hao-Chuan, Huang, Chun-Kai, Gao, He-Jin, Yang, Chia-Feng, Chan, Min-Ju, Lin, Wei-De, and Chen, Yann-Jang
- Subjects
- *
LYSOSOMAL storage diseases , *TANDEM mass spectrometry , *MEDICAL screening , *DRIED blood spot testing , *DIAGNOSIS ,DIAGNOSIS of neonatal diseases - Abstract
Abstract: Background: Interest in lysosomal storage diseases in newborn screening programs has increased in recent years. Two techniques, fluorescence (4-MU) and tandem mass spectrometry (MS/MS) methods are frequently used. We report a pilot study of large scale newborn screening for Fabry, Pompe, Gaucher, and MPS I diseases by using the MS/MS method in Taiwan and compared the performance of the MS/MS with 4-MU methods. Methods: More than 100,000 dried blood spots (DBSs) were collected consecutively as part of the national Taiwan newborn screening programs. The enzyme activities were detected by the MS/MS method from a DBS punch. Mutation analysis was further performed for newborns with detected enzyme deficiency. Results: The DNA sequence analysis for suspected cases revealed 64 newborns with confirmed Fabry mutations, 16 were classified as infantile or late-onset Pompe disease, and 1 was characterized as Gaucher disease. The positive predict value increased from 4.0% to 7.1% in the Pompe study, and from 61.0% to 95.5% in the Fabry study by the MS/MS method compared to 4-MU assay. Conclusions: The MS/MS method has been validated as a more specific, powerful and efficient tool than the 4-MU assay. It also provided a multiplex solution of newborn screening for lysosomal storage diseases. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
27. Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability.
- Author
-
Jap, Tjin-Shing, Chiu, Chih-Yang, Niu, Dau-Ming, Levine, Michael, and Levine, Michael A
- Subjects
- *
GENETIC mutation , *GENETIC disorders , *PHOSPHATES , *BIOCHEMICAL variation , *ENDOPEPTIDASES , *REVERSE transcriptase polymerase chain reaction - Abstract
Mutations in the phosphate-regulating endopeptidase homolog, X-linked, gene (PHEX), which encodes a zinc-dependent endopeptidase that is involved in bone mineralization and renal phosphate reabsorption, cause the most common form of hypophosphatemic rickets, X-linked hypophosphatemic rickets (XLH). The distribution of PHEX mutations is extensive, but few mutations have been identified in Chinese with XLH. We extracted genomic DNA and total RNA from leukocytes obtained from nine unrelated Chinese subjects (three males and six females, age range 11-36 years) who were living in Taiwan. The PHEX gene was amplified from DNA by PCR, and the amplicons were directly sequenced. Expression studies were performed by reverse-transcription PCR of leukocyte RNA. Serum levels of FGF23 were significantly greater in the patients than in normal subjects (mean 69.4 ± 18.8 vs. 27.2 ± 8.4 pg/mL, P < 0.005), and eight of the nine patients had elevated levels of FGF23. Germline mutations in the PHEX gene were identified in five of 9 patients, including novel c.1843 delA, donor splice site mutations c.663+2delT and c.1899+2T>A, and two previously reported missense mutations, p.C733Y and p.G579R. These data extend the spectrum of mutations in the PHEX gene in Han Chinese and confirm variability for XLH in Taiwan. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
28. The gene founder effect of two spontaneous mutations in ethnic Chinese (Taiwanese) CAH patients with 21-hydroxylase deficiency
- Author
-
Lee, Yann-Jinn, Tsai, Li-Ping, Niu, Dau-Ming, Shu, San-Ging, Chao, Mei-Chyn, and Lee, Hsien-Hsiung
- Subjects
- *
GENETIC mutation , *ADRENOGENITAL syndrome , *TAIWANESE people , *CYTOCHROME P-450 , *DEFICIENCY diseases , *NUCLEOTIDE sequence , *OLIGONUCLEOTIDES , *HLA histocompatibility antigens , *PATIENTS , *DISEASES - Abstract
Abstract: CYP21A2 mutations resulting from microconversions of the CYP21A1P sequence in congenital adrenal hyperplasia (CAH) commonly appear in all populations. However, it has not often been described as being due to the gene founder effect. Herein, we investigated two spontaneous mutations of IVS2+1G>A and R316X in ethnic Chinese (Taiwanese) CAH patients to determine whether they share the same haplotype of ancient origin by the analysis of sequence-specific oligonucleotide (SSO) for HLA class I B and sequence-based typing (SBT) for HLA class II DRB1 gene-typing methods. From over 200 CAH families, eight unrelated CAH patients were found and examined: five had the IVS2+1G>A mutation and three had the R316X mutation. Based on HLA typing data, five alleles in five patients with the IVS2+1G>A mutation were consistent with a shared haplotype of the B∗3909–DRB1∗160201 allele, and the three alleles in the three patients with the R316X mutation were all the B∗460101–DRB1∗080302 allele. The evidence indicates that the haplotype of single-base substitutions of either the IVS2+1G>A or R316X mutation came from the same allele rather than a mutational hot spot, suggesting that the gene founder effect has occurred in the Taiwanese population. This is the first report of the gene founder effect of the CYP21A2 mutation occurring in ethnic Chinese (Taiwanese) CAH patients with 21-hydroxylase deficiency. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
29. Electrophysiological Changes in Lipaemia Retinalis
- Author
-
Lu, Chao-Kung, Chen, Shih-Jen, Niu, Dau-Ming, Tsai, Chia-Chen, Lee, Fenq-Lih, and Hsu, Wen-Ming
- Subjects
- *
EYE diseases , *OPHTHALMOLOGY , *VISUAL acuity , *VISION disorders - Abstract
Purpose: To report the electrophysiologic findings in a patient with lipaemia retinalis. Design: Observational case report. Methods: An 11-year-old girl with diabetes had hyperlipidemia and presented for ophthalmologic consultation. Fundus examinations revealed milky discoloration of retinal vessels in both eyes. Laboratory testing disclosed hyperglycemia and markedly elevated level of triglycerides and cholesterol. Although the visual acuity was not affected, the electroretinograms showed decrease amplitudes of a- and b-wave in both cone and rod responses. Results: After correction of blood sugar and lipids with insulin and diet control, the lipaemia retinalis resolved, and the impaired ERG response reversed within 1 week. Conclusions: Lipaemia retinalis usually resolves rapidly without visual impairment after correction of hyperlipidemia. The reversible deficits of electroretinogram response in lipaemia retinalis are reported for the first time. High level of triglycerides or cholesterol or both may impair retinal function. The mechanism of an impaired electroretinogram remained speculative. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
30. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
- Author
-
Hsueh, Chien-Yu, Huang, Chii-Yuan, Yang, Chia-Feng, Chang, Chia-Chen, Lin, Wei-Sheng, Cheng, Hsiu-Lien, Wu, Shang-Liang, Cheng, Yen-Fu, and Niu, Dau-Ming
- Subjects
- *
GLYCOGEN storage disease type II , *EVOKED response audiometry , *AUDIOMETRY , *AUDITORY evoked response , *OTOACOUSTIC emissions , *HEARING disorders , *MEDICAL personnel - Abstract
Background: Studies suggest that enzyme-replacement therapy (ERT) is crucial to the survival of patients with infantile-onset Pompe disease (IOPD). Hearing impairment (HI) is one of the clinical sequelae observed in long-term survivors. However, the benefits of early ERT for hearing outcomes have not yet been reported. This study aimed to investigate the impact of early ERT on IOPD patients.Methods: This retrospective longitudinal study recruited IOPD patients who were referred by newborn screening for confirmatory diagnosis based on our rapid diagnostic criteria and received early ERT treatment between January 1, 2010, and January 31, 2018. The hearing test battery included a tympanogram, otoacoustic emission, auditory brainstem evoked response (ABR), pure-tone audiometry or conditioned play audiometry.Results: Nineteen patients with IOPD were identified, 6 of whom had hearing impairment (HI); 1 had conductive HI, 2 had sensorineural HI (one had bilateral mild HI and one had mild HI in a single ear) and 1 had moderate mixed-type HI. Two patients failed the newborn screening test and had mild HI in the ABR. The mean age of the initial time to ERT was 11.05 ± 4.31 days, and the HI rate was 31.6% (6/19).Conclusion: Our study is the largest cohort to show the characteristic hearing outcomes of IOPD patients after ERT. Early ERT within 2 weeks after birth may contribute to better hearing outcomes. Clinicians should be vigilant in testing for the hearing issues associated with IOPD and should intervene early if any HI is detected. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry disease.
- Author
-
Germain, Dominique P., Moiseev, Sergey, Suárez‐Obando, Fernando, Al Ismaili, Faisal, Al Khawaja, Huda, Altarescu, Gheona, Barreto, Fellype C., Haddoum, Farid, Hadipour, Fatemeh, Maksimova, Irina, Kramis, Mirelle, Nampoothiri, Sheela, Nguyen, Khanh Ngoc, Niu, Dau‐Ming, Politei, Juan, Ro, Long‐Sun, Vu Chi, Dung, Chen, Nan, and Kutsev, Sergey
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *GENETIC testing , *GENETIC disorders , *RARE diseases , *DELAYED diagnosis , *LYSOSOMES - Abstract
Background: Family genetic testing of patients newly diagnosed with a rare genetic disease can improve early diagnosis of family members, allowing patients to receive disease‐specific therapies when available. Fabry disease, an X‐linked lysosomal storage disorder caused by pathogenic variants in GLA, can lead to end‐stage renal disease, cardiac arrhythmias, and stroke. Diagnostic delays are common due to the rarity of the disease and non‐specificity of early symptoms. Newborn screening and screening of at‐risk populations, (e.g., patients with hypertrophic cardiomyopathy or undiagnosed nephropathies) can identify individuals with Fabry disease. Subsequent cascade genotyping of family members may disclose a greater number of affected individuals, often at younger age than they would have been diagnosed otherwise. Methods: We conducted a literature search to identify all published data on family genetic testing for Fabry disease, and discussed these data, experts' own experiences with family genetic testing, and the barriers to this type of screening that are present in their respective countries. Results: There are potential barriers that make implementation of family genetic testing challenging in some countries. These include associated costs and low awareness of its importance, and cultural and societal issues. Regionally, there are barriers associated with population educational levels, national geography and infrastructures, and a lack of medical geneticists. Conclusion: In this review, the worldwide experience of an international group of experts of Fabry disease highlights the issues faced in the family genetic testing of patients affected with rare genetic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II.
- Author
-
Lin, Hsiang-Yu, Chen, Ming-Ren, Lee, Chung-Lin, Lin, Shan-Miao, Hung, Chung-Lieh, Niu, Dau-Ming, Chang, Tung-Ming, Chuang, Chih-Kuang, and Lin, Shuan-Pei
- Subjects
- *
HEART valve diseases , *CARDIAC patients , *CARDIAC hypertrophy , *MUCOPOLYSACCHARIDOSIS , *MITRAL stenosis , *ENZYME replacement therapy , *ECHOCARDIOGRAPHY , *HEART , *MUCOPOLYSACCHARIDOSIS II , *DRUG therapy , *IMPACT of Event Scale , *RESEARCH funding - Abstract
Background: Cardiac abnormalities have been observed in patients with mucopolysaccharidosis type II (MPS II). The aim of this study was to investigate the cardiac features and natural progression of Taiwanese patients with MPS II, and evaluate the impact of enzyme replacement therapy (ERT) on cardiac structure and function.Methods: The medical records and echocardiograms of 48 Taiwanese patients with MPS II (median age, 6.9 years; age range, 0.1-27.9 years) were reviewed. The relationships between age and each echocardiographic parameter were analyzed.Results: The mean z-scores of left ventricular mass index (LVMI), interventricular septum diameter in diastole (IVSd), left ventricular posterior wall diameter in diastole (LVPWd), and aortic diameter were 1.10, 2.70, 0.95 and 1.91, respectively. Z scores > 2 were identified in 33%, 54%, 13%, and 46% for LVMI, IVSd, LVPWd, and aortic diameter, respectively. The most prevalent cardiac valve abnormality was mitral regurgitation (MR) (56%), followed by aortic regurgitation (AR) (33%). The severity of mitral stenosis (MS), MR, aortic stenosis (AS), AR, and the existence of valvular heart disease were all positively correlated with increasing age (p < 0.01). We also compared the echocardiographic parameters between two groups: (1) 12 patients who had up to 17 years of follow-up echocardiographic data without ERT, and (2) nine patients who had up to 12 years of follow-up data with ERT. The results showed that z-score changes of LVMI significantly improved in the patients who received ERT compared to those who did not receive ERT (0.05 versus 1.52, p < 0.05). However, the severity score changes of MS, MR, AS, and AR all showed gradual progression in both groups (p > 0.05).Conclusions: High prevalence rates of valvular heart disease and cardiac hypertrophy were observed in the MPS II patients in this study. The existence and severity of cardiac hypertrophy and valvular heart disease in these patients worsened with increasing age, reinforcing the concept of the progressive nature of this disease. ERT for MPS II appeared to be effective in stabilizing or reducing the progression of cardiac hypertrophy, but it only had a limited effect on valvulopathy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience.
- Author
-
Laney, Dawn A, Germain, Dominique P, Oliveira, João Paulo, Burlina, Alessandro P, Cabrera, Gustavo Horacio, Hong, Geu-Ru, Hopkin, Robert J, Niu, Dau-Ming, Thomas, Mark, Trimarchi, Hernán, Wilcox, William R, Politei, Juan Manuel, and Ortiz, Alberto
- Subjects
- *
COVID-19 , *ANGIOKERATOMA corporis diffusum , *MEDICAL personnel - Abstract
The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has raised questions about Fabry disease (FD) as an independent risk factor for severe COVID-19 symptoms. Available real-world data on 22 patients from an international group of healthcare providers reveals that most patients with FD experience mild-to-moderate COVID-19 symptoms with an additional complication of Fabry pain crises and transient worsening of kidney function in some cases; however, two patients over the age of 55 years with renal or cardiac disease experienced critical COVID-19 complications. These outcomes support the theory that pre-existent tissue injury and inflammation may predispose patients with more advanced FD to a more severe course of COVID-19, while less advanced FD patients do not appear to be more susceptible than the general population. Given these observed risk factors, it is best to reinforce all recommended safety precautions for individuals with advanced FD. Diagnosis of FD should not preclude providing full therapeutic and organ support as needed for patients with FD and severe or critical COVID-19, although a FD-specific safety profile review should always be conducted prior to initiating COVID-19-specific therapies. Continued specific FD therapy with enzyme replacement therapy, chaperone therapy, dialysis, renin–angiotensin blockers or participation to clinical trials during the pandemic is recommended as FD progression will only increase susceptibility to infection. In order to compile outcome data and inform best practices, an international registry for patients affected by Fabry and infected by COVID-19 should be established. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985-2019).
- Author
-
Lin, Hsiang-Yu, Lee, Chung-Lin, Chang, Chia-Ying, Chiu, Pao Chin, Chien, Yin-Hsiu, Niu, Dau-Ming, Tsai, Fuu-Jen, Hwu, Wuh-Liang, Lin, Shio Jean, Lin, Ju-Li, Chao, Mei-Chyn, Chang, Tung-Ming, Tsai, Wen-Hui, Wang, Tzu-Jou, Chuang, Chih-Kuang, and Lin, Shuan-Pei
- Subjects
- *
NEWBORN screening , *LIFE expectancy , *GENETIC disorders , *TAIWANESE people , *METABOLIC disorders , *AGE - Abstract
Background: Mucopolysaccharidoses (MPSs) are a group of inherited metabolic diseases, which are characterized by the accumulation of glycosaminoglycans, and eventually lead to the progressive damage of various tissues and organs.Methods: An epidemiological study of MPS in Taiwan was performed using multiple sources. The survival and diagnostic age for different types of MPS between 1985 and 2019 were evaluated.Results: Between 1985 and 2019, there were 175 patients diagnosed with MPS disorders in the Taiwanese population, with a median diagnostic age of 3.9 years. There were 21 (12%), 78 (45%), 33 (19%), 32 (18%) and 11 (6%) patients diagnosed with MPS I, II, III, IV and VI, respectively, with median diagnostic ages of 1.5, 3.8, 4.7, 4.5 and 3.7 years, respectively. Diagnosis of MPS patients was significantly earlier in recent decades (p < 0.01). Pilot newborn screening programs for MPS I, II, VI, IVA, and IIIB were progressively introduced in Taiwan from 2016, and 48% (16/33) of MPS patients diagnosed between 2016 and 2019 were diagnosed by one of these screening programs, with a median diagnostic age at 0.2 years. For patients born between 2016 and 2019, up to 94% (16/17) were diagnosed with MPS via the newborn screening programs. At the time of this study, 81 patients had passed away with a median age at death of 15.6 years. Age at diagnosis was positively correlated with life expectancy (p < 0.01). Life expectancy also significantly increased between 1985 and 2019, however this increase was gradual (p < 0.01).Conclusions: The life expectancy of Taiwanese patients with MPS has improved in recent decades and patients are being diagnosed earlier. Because of the progressive nature of the disease, early diagnosis by newborn screening programs and timely implementation of early therapeutic interventions may lead to better clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
35. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.
- Author
-
Lin, Hsiang‐Yu, Lee, Chung‐Lin, Lo, Yun‐Ting, Wang, Tuan‐Jen, Huang, Sung‐Fa, Chen, Tzu‐Lin, Wang, Yu‐Shan, Niu, Dau‐Ming, Chuang, Chih‐Kuang, and Lin, Shuan‐Pei
- Subjects
- *
INTERNAL medicine , *KIDNEY diseases , *LIVER function tests , *MEDICAL care , *MUCOPOLYSACCHARIDOSIS - Abstract
Background: The aim of this study was to use the liquid chromatography/tandem mass spectrometry (LC‐MS/MS) method to quantitate levels of three urinary glycosaminoglycans (GAGs; dermatan sulfate [DS], heparan sulfate [HS], and keratan sulfate [KS]) to help make a correct diagnosis of mucopolysaccharidosis (MPS). Methods: We analyzed the relationships between phenotypes and levels of urinary GAGs of 79 patients with different types of MPS. Results: The patients with mental retardation (n = 21) had significantly higher levels of HS than those without mental retardation (n = 58; 328.8 vs. 3.2 μg/ml, p < 0.001). The DS levels in the patients with hernia, hepatosplenomegaly, claw hands, coarse face, valvular heart disease, and joint stiffness were higher than those without. Twenty patients received enzyme replacement therapy (ERT) for 1–12.3 years. After ERT, the KS level decreased by 90% in the patients with MPS IVA compared to a 31% decrease in the change of dimethylmethylene blue (DMB) ratio. The DS level decreased by 79% after ERT in the patients with MPS VI compared to a 66% decrease in the change of DMB ratio. Conclusions: The measurement of GAG fractionation biomarkers using the LC‐MS/MS method is a more sensitive and reliable tool than the DMB ratio for MPS high‐risk screening, diagnosis, subclass identification, and monitoring the efficacy of ERT. The measurement of GAG fractionation biomarkers using the LC‐MS/MS method is a more sensitive and reliable tool than the DMB ratio for MPS high‐risk screening, diagnosis, subclass identification, and monitoring the efficacy of ERT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
- Author
-
Chen, Kuan-Hsuan, Chou, Yueh-Ching, Hsiao, Chen-Yuan, Chien, Yueh, Wang, Kang-Ling, Lai, Ying-Hsiu, Chang, Yuh-Lih, Niu, Dau-Ming, and Yu, Wen-Chung
- Subjects
- *
SERUM , *ENZYMES , *ANGIOKERATOMA corporis diffusum , *CARDIOMYOPATHIES , *OXIDATIVE stress - Abstract
Objectives The level of 8-hydroxy-2-deoxyguanosise (8-OHdG) is a marker of oxidative stress. The objective of this study was to evaluate the effect of enzyme replacement therapy (ERT) on the level of 8-OHdG in patients with Fabry cardiomyopathy and the clinical evolution of Fabry cardiomyopathy. Methods We measured the serum levels of 8-OHdG in 20 healthy control and 22 patients with Fabry cardiomyopathy before and after ERT. Results The mean lysoGb3 and 8-OHdG levels was significantly increased in patients with Fabry cardiomyopathy compared with that of control subjects (lysoGb3, 3.6 ± 1.1 nM vs. 0.4 ± 0.1 nM, p < 0.01 ; 8-OHdG, 4.5 ± 0.5 ng/mL vs. 3.4 ± 0.4 ng/mL, P < 0.05 ). The mean lysoGb3 and 8-OHdG levels was significantly reduced after ERT for 14.2 months (lysoGb3, 3.6 ± 1.1 nM vs. 2.9 ± 1.1 nM, P < 0.05 ; 8-OHdG, 4.5 ± 0.5 ng/mL to 4 ± 0.4 ng/mL, P < 0.05 ). These changes were accompanied by decreases in LVM and LVMI. Conclusions We demonstrated that the serum 8-OHdG levels is increased in patients with Fabry cardiomyopathy (FC) and that successful management of FC with ERT is associated with a decrease in this oxidative stress marker. Serum 8-OHdG levels can be used not only as a noninvasive biomarker of oxidative stress in patients with FC but also an objective and quantitative parameter in the follow-up of patients during ERT. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
- Author
-
Chou, Shih-Jie, Yu, Wen-Chung, Chang, Yuh-Lih, Chen, Wen-Yeh, Chang, Wei-Chao, Chien, Yueh, Yen, Jiin-Cherng, Liu, Yung-Yang, Chen, Shih-Jen, Wang, Chien-Ying, Chen, Yu-Han, Niu, Dau-Ming, Lin, Shing-Jong, Chen, Jaw-Wen, Chiou, Shih-Hwa, and Leu, Hsin-Bang
- Subjects
- *
BIOENERGETICS , *PLURIPOTENT stem cells , *HEART cells , *ANGIOKERATOMA corporis diffusum , *THERAPEUTICS , *GLYCOSPHINGOLIPIDS , *BIOACCUMULATION - Abstract
Background Fabry disease (FD) is a lysosomal storage disease in which glycosphingolipids (GB3) accumulate in organs of the human body, leading to idiopathic hypertrophic cardiomyopathy and target organ damage. Its pathophysiology is still poorly understood. Objectives We aimed to generate patient-specific induced pluripotent stem cells (iPSC) from FD patients presenting cardiomyopathy to determine whether the model could recapitulate key features of the disease phenotype and to investigate the energy metabolism in Fabry disease. Methods Peripheral blood mononuclear cells from a 30-year-old Chinese man with a diagnosis of Fabry disease, GLA gene (IVS4 + 919G > A) mutation were reprogrammed into iPSCs and differentiated into iPSC-CMs and energy metabolism was analyzed in iPSC-CMs. Results The FD-iPSC-CMs recapitulated numerous aspects of the FD phenotype including reduced GLA activity, cellular hypertrophy, GB3 accumulation and impaired contractility. Decreased energy metabolism with energy utilization shift to glycolysis was observed, but the decreased energy metabolism was not modified by enzyme rescue replacement (ERT) in FD-iPSCs-CMs. Conclusion This model provided a promising in vitro model for the investigation of the underlying disease mechanism and development of novel therapeutic strategies for FD. This potential remedy for enhancing the energetic network and utility efficiency warrants further study to identify novel therapies for the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
- Author
-
Auray-Blais, Christiane, Lavoie, Pamela, Boutin, Michel, Ntwari, Aimé, Hsu, Ting-Rong, Huang, Chun-Kai, and Niu, Dau-Ming
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *BIOMARKERS , *GENETIC mutation , *DISEASE incidence , *LEFT ventricular hypertrophy - Abstract
Background Fabry disease is a lysosomal storage disorder with an incidence of 1:1600 for the late-onset IVS4 + 919G > A cardiac variant mutation in Taiwan. Signs and symptoms of this cardiac variant include left ventricular hypertrophy, mitral insufficiency and/or arrhythmias. The search for biomarkers that might predict the clinical outcomes and guide treatment options is important. We thus investigated relationships between Fabry disease biomarkers (such as globotriaosylceramide (Gb 3 ), globotriaosylsphingosine (lyso-Gb 3 )/related analogues) and age, gender, enzyme activity, clinical manifestations and severity of the disease in these patients. Method Urine and plasma biomarkers were analyzed using tandem mass spectrometry. A large cohort of 191 adult and pediatric Fabry patients carrying the IVS4 + 919G > A mutation was studied. Some patients were members of the same family. Results Our results show that the plasma lyso-Gb 3 level, and urinary analogue levels of lyso-Gb 3 at m / z (+ 16), (+ 34), and (+ 50) adjusted for gender and age had a positive association with the left ventricular mass index, and/or the Mainz Severity Score Index. Conclusions It might thus be of particular interest to monitor children with high levels of these biomarkers, as part of a longitudinal study in order to determine if the excretion profile at a young age is predictive of the outcomes of disease severity in adulthood. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation.
- Author
-
Han-Jui Lee, Ting-Rong Hsu, Sheng-Che Hung, Wen-Chung Yu, Tzu-Hung Chu, Chia-Feng Yang, Bizjajeva, Svetlana, Chui-Mei Tiu, Dau-Ming Niu, Lee, Han-Jui, Hsu, Ting-Rong, Hung, Sheng-Che, Yu, Wen-Chung, Chu, Tzu-Hung, Yang, Chia-Feng, Tiu, Chui-Mei, and Niu, Dau-Ming
- Subjects
- *
THERAPEUTICS , *ANGIOKERATOMA corporis diffusum , *CENTRAL nervous system diseases , *MAGNETIC resonance imaging , *TAIWANESE people , *BASILAR artery , *PHYSIOLOGY , *SURGERY , *DISEASE risk factors , *HEALTH , *AGE factors in disease , *COMPARATIVE studies , *GLYCOSIDASES , *ISOENZYMES , *RESEARCH methodology , *MEDICAL cooperation , *GENETIC mutation , *RESEARCH , *EVALUATION research , *RETROSPECTIVE studies - Abstract
Background: Patients with the later-onset IVS4+919G>A (IVS4) Fabry mutation are known to have positive central nervous system involvement compared with age- and sex-matched controls. This study compares central nervous system manifestations in patients with the IVS4 mutation or classical Fabry mutations.Methods: This was a retrospective analysis of magnetic resonance imaging (MRI) data from Taiwanese patients enrolled in the Fabry Outcome Survey (sponsored by Shire; data extracted March 2015).Results: Twenty-five IVS4 (19 males) and 12 (four males) classical Fabry patients underwent MRI at a median (range) age of 60.7 (45.0-70.4) and 43.0 (18.0-61.4) years, respectively. All patients received agalsidase alfa enzyme replacement therapy; two (16.7%) classical Fabry patients underwent MRI before treatment start. The pulvinar sign occurred in eight (32.0%; seven males) IVS4 and six (50.0%; three males) classical Fabry patients. Infarction occurred in eight (32.0%) IVS4 and four (33.3%) classical Fabry patients. Fazekas scores of 0, 1, 2, and 3 were found for 15 (60.0%), seven (28.0%), two (8.0%), and one (4.0%) of the IVS4 patients and for six (50.0%), four (33.3%), two (16.7%), and 0 classical Fabry patients, respectively. Abnormal height bifurcation of the basilar artery was observed in 40.0% of IVS4 and 58.3% of classical Fabry patients; abnormal laterality was observed in 4.0% of IVS4 and 16.7% of classical Fabry patients. Median (range) basilar artery diameter was 2.7 (1.4-4.0) mm in IVS4 and 3.2 (2.3-4.7) mm in classical Fabry patients (P = 0.0293); vascular stenosis was noted in 8.3% of IVS4 patients but in no classical Fabry patients.Conclusions: A similar range of MRI findings was found for both IVS4 and classical Fabry patients. Notably, basilar artery diameter was larger in classical Fabry patients than IVS4 patients. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
40. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey.
- Author
-
Giugliani, Roberto, Hughes, Derralynn, Nicholls, Kathy, Niu, Dau-Ming, Reisin, Ricardo C., Botha, Jaco, Anagnostopoulou, Christina, and West, Michael L.
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *TREATMENT effectiveness - Published
- 2023
- Full Text
- View/download PDF
41. Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy.
- Author
-
Lai, Chih-Jou, Hsu, Ting-Rong, Yang, Chia-Feng, Chen, Shyi-Jou, Chuang, Ya-Chin, and Niu, Dau-Ming
- Subjects
- *
GLYCOGEN storage disease type II , *GLYCOGEN storage disease , *COGNITIVE development , *INBORN errors of metabolism , *CARBOHYDRATE metabolism disorders , *LIVER glycogenic function - Abstract
Most patients with infantile-onset Pompe disease die in early infancy before beginning enzyme replacement therapy, which has made it difficult to evaluate the impact of Pompe disease on cognitive development. Patients with infantile-onset Pompe disease can survive with enzyme replacement therapy, and physicians can evaluate cognitive development in these patients. We established an effective newborn screening program with quick clinical diagnostic criteria. Cognitive and motor development were evaluated using the Bayley Scales of Infant and Toddler Development–Third Edition at 6, 12, and 24 months of age. The patients who were treated very early demonstrate normal cognitive development with no significant change in cognition during this period (P = .18 > .05). The cognitive development was positively correlated with motor development (r = 0.533, P = .011). The results indicated that very early enzyme replacement therapy could protect cognitive development in patients with infantile-onset Pompe disease up to 24 months of age. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Clinical characteristics and demographics in patients 50 years and older in the Fabry Outcome Survey (FOS).
- Author
-
Lidove, Olivier, Barbey, Frédéric, Niu, Dau-Ming, Brand, Eva, Nicholls, Kathleen, Bizjajeva, Svetlana, and Hughes, Derralynn
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *HEALTH outcome assessment , *HEALTH surveys , *DISEASES in older people , *MEDICAL research , *PATIENTS - Published
- 2016
- Full Text
- View/download PDF
43. Epigenotype, genotype, and phenotype analysis of patients in Taiwan with Beckwith–Wiedemann syndrome.
- Author
-
Lin, Hsiang-Yu, Chuang, Chih-Kuang, Tu, Ru-Yi, Fang, Yi-Ya, Su, Yi-Ning, Chen, Chih-Ping, Chang, Chia-Ying, Liu, Hsi-Che, Chu, Tzu-Hung, Niu, Dau-Ming, and Lin, Shuan-Pei
- Subjects
- *
GENOTYPES , *PHENOTYPES , *BECKWITH-Wiedemann syndrome , *GENE expression , *CHROMOSOMES , *METHYLATION - Abstract
Background Beckwith–Wiedemann syndrome (BWS) is a congenital overgrowth disorder predisposing to tumorigenesis that results from abnormal expression or function of imprinted genes of chromosome 11p15.5. Methods Forty-seven patients in Taiwan with clinical suspicion of BWS were referred for diagnostic testing based on methylation profiling of H19 -associated imprinting center (IC) 1 and KCNQ1OT1 -associated IC2 using high-resolution melting analysis, multiplex ligation-dependent probe amplification, or high-resolution quantitative methylation profiling. Results Twenty-eight patients received a clinical diagnosis of BWS (the presence of 3 major features or 2 major features and at least 1 minor feature), 18 had suspected BWS (the presence of at least 1 major feature), and 1 had isolated Wilms' tumor. Nineteen patients were identified with IC2 hypomethylation (including 1 with isolated Wilms' tumor), 1 with IC1 hypermethylation, 2 with paternal uniparental disomy, and 1 with CDKN1C mutation. Several clinical features were found to be statistically different ( P < 0.05) between the 2 groups—clinical diagnosis of BWS (n = 28) or suspected BWS (n = 18)—including macroglossia, pre- or postnatal gigantism, abdominal wall defect, ear creases, facial nevus flammeus, BWS score, and the molecular diagnosis rate. Molecular lesion was detected in 81% of patients with the presence of three major features, compared with 33% and 28% of those with two or one major feature, respectively. The mean BWS score was 5.6 for 19 subjects with “IC2 hypomethylation”, compared with 3.8 for 2 subjects with pUPD. The BWS score of one subject with CDKN1C mutation and one with IC1 hypermethylation was 6 and 7, respectively. Conclusions The BWS score was positively correlated with the molecular diagnosis rate ( P < 0.01). The BWS database of epigenotype, genotype, and phenotype is expected to promote better genetic counseling and medical care of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Functional independence of Taiwanese children with Down syndrome.
- Author
-
Lin, Hsiang‐Yu, Chuang, Chih‐Kuang, Chen, Yen‐Jiun, Tu, Ru‐Yi, Chen, Ming‐Ren, Niu, Dau‐Ming, and Lin, Shuan‐Pei
- Subjects
- *
DOWN syndrome , *DEVELOPMENTAL disabilities , *INTELLECTUAL disabilities , *BRAIN diseases , *GENEALOGY , *QUESTIONNAIRES , *HEALTH self-care , *ACTIVITIES of daily living , *CHILDREN with disabilities - Abstract
Aim: Information regarding the functional strengths and weaknesses of children with Down syndrome is important for early intervention programmes and for agencies providing family support and educational services.Method: This study used the Functional Independence Measure for Children (WeeFIM) questionnaire for the parents or caregivers of 166 Taiwanese children (101 males and 65 females; median age 12y 7mo; range 3y 2mo-19y 1mo) with Down syndrome to assess their functional skills.Results: Out of a potential score of 126, the mean total WeeFIM score was 101.2. There was no statistically significant difference between the scores from the male and female participants (100.4 [SD 21.4] vs 102.4 [SD 24.7]; p>0.05). The mean scores for three domains (self-care, mobility, and cognition) were 45, 33, and 23 respectively (maximum of 56, 35, and 35 respectively). Performance was strongest in the mobility domain and weakest in the cognition domain. The total WeeFIM scores and 18 subscores for the three domains all positively correlated with age (p<0.05).Interpretation: For children with Down syndrome, some support and supervision is required for cognition and self-care tasks. The WeeFIM questionnaire may be useful for identifying the strengths and limitations of children with developmental disabilities and their families. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
45. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
- Author
-
Lin, Hsiang-Yu, Chuang, Chih-Kuang, Chen, Ming-Ren, Lin, Shan-Miao, Hung, Chung-Lieh, Chang, Chia-Ying, Chiu, Pao Chin, Tsai, Wen-Hui, Niu, Dau-Ming, Tsai, Fuu-Jen, Lin, Shio Jean, Hwu, Wuh-Liang, Lin, Ju-Li, and Lin, Shuan-Pei
- Subjects
- *
HEART anatomy , *THERAPEUTIC use of enzymes , *TREATMENT effectiveness , *MUCOPOLYSACCHARIDOSIS I , *MUCOPOLYSACCHARIDOSIS II , *MUCOPOLYSACCHARIDOSIS IV - Abstract
Background While enzyme replacement therapy (ERT) has been shown to improve endurance and joint mobility for patients with mucopolysaccharidoses (MPS) I, II, IVA and VI, the impact of ERT on cardiac abnormalities remains uncertain. Methods Medical records and echocardiograms of 28 Taiwanese MPS patients (9 with MPS I, 7 with MPS II, 7 with MPS IVA, and 5 with MPS VI) treated with ERT for 1–10.8 years were retrospectively reviewed. Results At start of ERT, z scores > 2 were identified in 46% and 75% for left ventricular mass index (LVMI) and interventricular septum thickness in diastole (IVSd) in these patients, respectively. Twenty-four patients (86%) had valvular heart disease. After ERT, the mean IVSd z score of all patients decreased significantly from 3.87 to 2.57 ( p = 0.016). For 11 patients starting ERT before 12 years of age, z scores for both LVMI and IVSd decreased significantly ( p < 0.01) after ERT. However, the condition of valve regurgitation or stenosis did not show improvement despite ERT. Conclusions ERT was shown to be an effective therapy for reducing cardiac hypertrophy, with best results seen when ERT was started at an early age. ERT, however, had little impact on valvular heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Measuring propionyl-CoA carboxylase activity in phytohemagglutinin stimulated lymphocytes using high performance liquid chromatography.
- Author
-
Liu, Yu-Ning, Liu, Tze-Tze, Fan, Ya-Ling, Niu, Dau-Ming, Chien, Yin-Hsiu, Chou, Yen-Yin, Lee, Ni-Chung, Hsiao, Kwang-Jen, and Chiu, Yen-Hui
- Subjects
- *
PROPIONYL-CoA carboxylase , *PHYTOHEMAGGLUTININS , *LYMPHOCYTES , *HIGH performance liquid chromatography , *MITOCHONDRIAL enzymes - Abstract
Background Propionyl-CoA carboxylase (PCC) is a mitochondrial enzyme involved in the catabolism of several essential amino acids and odd chain fatty acids. Previous PCC assays have involved either a radiometric assay or have required mitochondria isolation and/or enzyme purification. Methods We developed an enzymatic method to analyze PCC activity in phytohemagglutinin (PHA) stimulated lymphocytes that involves high performance liquid chromatography. Results The method shows good linearity and sensitivity. PCC activity was unaffected even when lymphocytes were isolated and PHA stimulated after a whole blood sample had been stored at 4 °C for 5 days. This indicates that this method is suitable for analyzing samples from distant medical centers. The PCC activity of patients with propionic acidemia was found to be much lower than that of normal individuals and carriers. However, this PCC assay is significantly affected by the red blood cell contamination. In conclusion, this is a reliable method for performing PCC assays and only requires 0.5 to 1.0 ml of whole blood from newborns. Conclusions The PCC assay established in this study is useful for the confirmation of PA in individuals, and prenatal diagnosis and genetic counseling for the affected families. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta.
- Author
-
Hsiang-Yu Lin, Chih-Kuang Chuang., Yi-Ning Su, Ming-Ren Chen, Hui-Chin Chiu, Dau-Ming Niu, Shuan-Pei Lin, Lin, Hsiang-Yu, Chuang, Chih-Kuang, Su, Yi-Ning, Chen, Ming-Ren, Chiu, Hui-Chin, Niu, Dau-Ming, and Lin, Shuan-Pei
- Subjects
- *
OSTEOGENESIS imperfecta , *PHENOTYPES , *BONE density , *RETROSPECTIVE studies , *GENOTYPES , *DIAGNOSIS - Abstract
Background: Osteogenesis imperfecta (OI) is a congenital disorder characterized by increased bone fragility and low bone mass.Methods: The presence of COL1A1 or COL1A2 mutation was investigated by direct sequencing in 72 patients with OI type I, III, or IV (27 males and 45 females; age range 0.2-62 years) from 37 unrelated families. The clinical features of these patients were also recorded.Results: Thirty-seven COL1A1 and COL1A2 mutations were identified, including 28 COL1A1 mutations and 9 COL1A2 mutations. Fifteen (41%) were novel mutations, and twelve (32%) were familial mutations. A review of their medical records revealed that the 72 patients could be classified into OI type I (n = 42), III (n = 5), and IV (n = 25). Twenty-nine patients had helical mutations (caused by the substitution of a glycine within the Gly-X-Y triplet domain of the triple helix), and 42 had haploinsufficiency mutations (caused by frameshift, nonsense, and splice-site mutations). Compared with haploinsufficiency, the patients with helical mutations had more severely impaired skeletal phenotypes, including shorter height, lower bone mineral density, poorer walking ability, more frequent manifestations of dentinogenesis imperfecta and scoliosis (p < 0.05).Conclusions: Genotype and phenotype databases are expected to promote better genetic counseling and medical care of patients with OI. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
48. Two Frequent Mutations Associated with the Classic Form of Propionic Acidemia in Taiwan.
- Author
-
Chiu, Yen-Hui, Liu, Yu-Ning, Liao, Wei-Ling, Chang, Ying-Chen, Lin, Shuan-Pei, Hsu, Chia-Chi, Chiu, Pao-Chin, Niu, Dau-Ming, Wang, Chung-Hsing, Ke, Yu-Yuan, Chien, Yin-Hsiu, Hsiao, Kwang-Jen, and Liu, Tze-Tze
- Subjects
- *
GENETIC mutation , *ACIDOSIS , *PROPIONYL-CoA carboxylase , *BRANCHED chain amino acids , *CHOLESTEROL metabolism , *PHENOTYPES - Abstract
Propionyl-CoA carboxylase (PCC) is involved in the catabolism of branched chain amino acids, odd-numbered fatty acids, cholesterol, and other metabolites. PCC consists of two subunits, α and β, encoded by the PCCA and PCCB genes, respectively. Mutations in the PCCA or PCCB subunit gene may lead to propionic acidemia. In this study, we performed mutation analysis on ten propionic acidemia patients from eight unrelated and nonconsanguineous families in Taiwan. Two PCCA mutations, c.229C→T (p.R77W) and c.1262A→C (p.Q421P), were identified in a PCCA-deficient patient. Six mutations in the PCCB gene, including c.-4156_183+3713del, c.580T→C (p.S194P), c.838dup (p.L280Pfs*11), c.1301C→T (p.A434V), c.1316A→G (P.Y439C), and c.1534C→T (p.R512C), were identified in seven PCCB-deficient families. The c.-4156_183+3713del mutation is the first known large deletion that affects the PCCB gene functions. Furthermore, the c.1301C→T and c.-4156_183+3713del mutations in the PCCB gene have not been reported previously. Clinical features demonstrated that these two frequent mutations are associated with low enzyme activity and a classic propionic acidemia phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses.
- Author
-
Lin, Hsiang-Yu, Shih, Shou-Chuan, Chuang, Chih-Kuang, Lee, Kuo-Sheng, Chen, Ming-Ren, Lin, Hung-Ching, Chiu, Pao Chin, Niu, Dau-Ming, and Lin, Shuan-Pei
- Subjects
- *
HEARING disorders , *AUDIOMETRY , *MUCOPOLYSACCHARIDOSIS , *OTOLARYNGOLOGICAL nursing , *FOLLOW-up studies (Medicine) , *DATA analysis , *PATIENTS - Abstract
Abstract: Background: Patients with mucopolysaccharidoses (MPS) often have hearing loss. However, the characterization of hearing loss by pure-tone audiometry (PTA) in this rare disease population and its relationship to age and treatment is limited. Methods: PTA was performed in 39 patients with MPS (29 males and 10 females; 3 with MPS I, 21 with MPS II, 9 with MPS IVA, and 6 with MPS VI; median age, 11.9years; age range, 4.4–34.2years). The degree of hearing loss was classified by the age-independent World Health Organization (WHO) clinical guidelines. Results: Hearing loss by PTA was present in 85% (33/39) of patients and was categorized as mild (26–40dB) in 18%, moderate (41–60dB) in 36%, severe (61–80dB) in 23%, and profound (≥81dB) in 5%. Among the patients with hearing loss, 33% were classified as mixed type (conductive and sensorineural), 30% as pure conductive type, 27% as pure sensorineural type, and 9% were undefined. The means of the right and left ear hearing thresholds at 2000 and 4000Hz by air conduction (AC) and at 500, 1000, 2000, and 4000Hz by bone conduction (BC) were all positively correlated with age (p <0.05). In the 6 patients with MPS II or VI who underwent follow-up PTA after ventilation tube insertion and enzyme replacement therapy for 1.9 to 8.5years, all showed improvements in AC and BC of the better ear, as well as in the air-bone gap. Conclusions: Hearing impairment is common in MPS. Early otolaryngological evaluation and intervention are recommended. These findings and the follow-up data can be used to develop quality of care strategies for patients with MPS. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
50. High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry.
- Author
-
Lee, Sheng-Hung, Li, Cheng-Fang, Lin, Hsiang-Yu, Lin, Chien-Hsing, Liu, Hao-Chuan, Tsai, Shih-Feng, and Niu, Dau-Ming
- Subjects
- *
SEQUENCE analysis , *ANGIOKERATOMA corporis diffusum , *TAIWANESE people , *MASS spectrometry , *DNA analysis , *BIOLOGICAL assay , *DISEASES - Abstract
Abstract: Background: In view of the therapeutic benefits resulting from early intervention for Fabry disease, our team has implemented an enzyme-based newborn screening in Taiwan since 2008. However, we found that most heterozygous females cannot be detected. To improve the screening efficiency, a more effective method for GLA gene genotyping is necessary. Methods: As the suspected mutations are limited to only 29 different spots in Taiwanese, a panel of Sequenom iPLEX assay was designed for rapid screening of GLA variations. To determine the accuracy and sensitivity of this assay, previously diagnosed and undiagnosed DNA samples were analyzed by this genotyping assay and Sanger sequencing. In addition, DNA extracted from dried blood spots was also tested. Results: Sequenom iPLEX assay is accurate and cost-effective, identifying the sequence variations, which were designated in the panel. It identified common GLA variants in DNA samples extracted from whole blood or dried blood spots with 100% accuracy and sensitivity. Conclusions: Sequenom iPLEX assay is suitable for Fabry newborn screening when hotspot mutations and common variations are known in a well-studied population. In addition, this assay can also be applied for first-line determination of GLA variant sequences in suspected subjects of high-risk patients, or newborns. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.